Upstream Bio (UPB) EBITDA (2023 - 2026)

Upstream Bio's EBITDA history runs 4 years deep, the most recent figure standing at -$43.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 36.24% year-over-year to -$43.6 million; the TTM figure through Mar 2026 stood at -$172.0 million (down 81.46% YoY), while the FY2025 annual figure was -$160.4 million, down 106.21% from the prior year.
• EBITDA for Q1 2026 stood at -$43.6 million, up from -$46.2 million in the prior quarter.
• The five-year high for EBITDA was -$9.4 million in Q3 2023, with the low at -$46.2 million in Q4 2025.
• The 4-year median for EBITDA is -$26.3 million (2024), against an average of -$27.8 million.
• The sharpest annual moves came in 2025 and 2026: EBITDA slumped 152.83% in 2025, then tumbled 36.24% in 2026.
• Upstream Bio's EBITDA stood at -$14.3 million in 2023, then slumped by 83.66% to -$26.3 million in 2024, then sank by 75.42% to -$46.2 million in 2025, then rose by 5.53% to -$43.6 million in 2026.
• Business Quant data shows UPB's EBITDA at -$43.6 million in Q1 2026, -$46.2 million in Q4 2025, and -$37.8 million in Q3 2025.